Nab-sirolimus not checked
Aadi Bioscience, Inc. · ABI-009
FollowEvery change as it happens, and a Monday email
Trials
87 active
110 in total · 99 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Prospective Phase 2, open-label, multi-institutional study to evaluate the efficacy and safety of nab-sirolimus + letrozole in patients”In the company’s words, NCT05997017 on ClinicalTrials.gov
- Tested for
- Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor, Recurrent Endometrial Carcinoma, Endometrioid Endometrial Cancer
- Main trialPhase 2
- “A Phase 2 Multi-center Open-label Trial of nab-Sirolimus in Combination with Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer”In the company’s words, NCT05997017 on ClinicalTrials.gov
- Other names
- ABI-009 · temozolomide · bevacizumab · radiation · nab-rapamycin · Fyarro
Other drugs for Endometrial Cancer
- PembrolizumabMerck & Co. · Phase 3
- Trastuzumab deruxtecanDaiichi Sankyo · AstraZeneca · Phase 3
- Puxitatug SamrotecanAstraZeneca · Phase 3
- RilvegostomigAstraZeneca · Phase 3
- Anlotinib HydrochlorideChia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase 3
- Sacituzumab tirumotecanKelun-Biotech · Merck & Co. · Phase 3
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials110
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | Dec 2026 | Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | |
| Phase 2Completed | Nov 2021 | A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa | |
| Phase 2Completed | 26 Aug 2022 | Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma | |
| Phase 2Completed | 23 Dec 2024 | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | |
| Phase 2Withdrawn | 31 Dec 2024 | ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome | |
| Phase 2Completed | 3 Oct 2025 | Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | |
| Phase 1/2Completed | 1 Dec 2019 | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | |
| Phase 1/2Completed | 16 Aug 2022 | Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer | |
| Phase 1Completed | 16 Aug 2022 | Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension | |
| Phase 1Terminated | 27 Dec 2024 | Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) | |
| Phase 1Completed | 19 Aug 2025 | Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment | |
| Phase 3Authorised | not given | StrateGlio: Phase III randomised trial evaluating early treatment intensification with temozolomide in adults with a glioblastoma | |
| Phase 2Authorised | not given | TERTIO : Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a proof of concept randomized phase II study | |
| Phase 2/3Ended | not given | PRODIGE 81-FFCD 2101-TRIPLET: Randomized, open-label, phase II-III study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patients with hepatocellular carcinoma receiving first-line systemic therapy | |
| Phase 2Authorised | not given | MetroWILMS-1906: Phase 1-2 trial evaluating metronomic chemotherapy in patients with relapsed or refractory Wilms tumor | |
| Phase 2Authorised | not given | Preoperative immunotherapy with atezolizumab (Tecentriq®) and tiragolumab or atezolizumab (Tecentriq®) and bevacizumab (Avastin®) in patients with colorectal liver metastases (CRLM) (the PURPLE trial) | |
| Phase 2Ended | not given | SLURP; A phase 2 intervention study: Detection of early esophageal neoplastic lesions by quantified fluorescence molecular endoscopy using oral and topical administration of bevacizumab-800CW and cetuximab-800CW | |
| Phase 2Authorised | not given | A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer Following a Front-Line Complete Cytoreductive Surgery (NIRVANA-1 study) | |
| Phase 3Authorised | not given | PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with positive ctDNA after surgery and adjuvant chemotherapy for a high-risk stage II and stage III Colorectal Cancer | |
| Phase 2Ended | not given | Phase II study evaluating Holmium-166 TARE followed by maIntenance Therapy in liver limited unresectable colorectal cancer patients after first-lIne chemotherapy and target agents: The HAITI study. | |
| Phase 2Authorised | not given | Immunological variables associated to ICI toxicity in cancer patients | |
| Phase 2Ended | not given | The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration | |
| Phase 1/2Authorised | not given | DETOUR; Determining the safety and feasibility of optical coherence tomography and near infrared fluorescence: a prospective pilot intervention study | |
| Phase 3Authorised | not given | PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 Study | |
| Phase 3Authorised | not given | Phase III trial of lomustine/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT promoter methylated glioblastoma (IDHwt) patients +/- tumor treating fields (Optune) | |
| Phase 3/4Authorised | not given | Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastatique non résécable : étude de phase 3 randomisée multicentrique en double aveugle. | |
| Phase 2Authorised | not given | Improving public cancer care by implementing precision medicine in Norway A multi-cohort phase 2 treatment clinical study investigating efficacy of approved drugs outside indication in patients with advanced cancer. IMPRESS-Norway | |
| Phase 2Authorised | not given | BevacizuMAV : Evaluation of the efficacy and safety of anti-angiogenic treatment with intravenous bevacizumab in patients with symptomatic cerebral arteriovenous malformations | |
| Phase 2Authorised | not given | TRIFLUOX-DP: Safety of Trifluridine/tipiracil as replacement of fluoropyrimidines (5-fluorouracil and capecitabine) based chemotherapy as first line metastatic colorectal or gastroesophageal cancer regimens in patients with dihydropyrimidine dehydrogenase deficiency: a phase II trial | |
| Phase 2Authorised | not given | A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile: The Drug Rediscovery Protocol (DRUP trial) | |
| Phase 2Authorised | not given | Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial | |
| Phase 4Authorised | not given | zAvatar test-guided therapeutic decision vs standard of care, in relapsed ovarian cancer and in metastatic breast cancer - A multicentric randomized clinical study with intervention | |
| Phase 4Authorised | not given | A multi-centre, four-arm, randomised, double-blind study assessing the dose equivalence of bevacizumab in first-line therapy for ovarian cancer | |
| Phase 3Authorised | not given | A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS | |
| Phase 2Authorised | not given | NeoAdjuvant PErsonalized therapy in Estrogen Receptor positive breast cancer (NAPEER) - An open label phase II trial of endocrine treatment with or without capivasertib, followed by response assessment before neoadjuvant chemotherapy with bevacizumab (if ViRP signature positive). | |
| Phase 2Authorised | not given | Fecal Microbiota Transplantation to RESCUE patients with unresectable Hcc progressors to first line therapy with AtezolizUmaB and Bevacizumab (RESCUE-HUB) | |
| Phase 1/2Authorised | not given | TARLATEM : Combination of TARLAtamab and TEMozolomide in patients with central nervous system tumors. A multicenter, open-label Phase I/II trial aiming to assess the safety and clinical activity of Tarlatamab in combination with metronomic Temozolomide in adolescents and adults’ patients with high grade brain tumors | |
| Phase 3Authorised | not given | SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. | |
| Phase 1/2Authorised | not given | FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma | |
| Phase 3Authorised | not given | Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial (IMPROVE CODEL) | |
| Phase 2Authorised | not given | Feasibility of fluorescence imaging with bevacizumab-800CW during bronchoscopy in patients with a pulmonary lesion considered to be malignant - DFLECT I | |
| Phase 3Authorised | not given | Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled double-blind phase III study, comparing bevacizumab versus placebo (BRADI) | |
| Phase 2Authorised | not given | An Italian multicenter phase II trial of Metronomic Temozolomide in unfit patients with advanced neuroendocrine neoplasms (NENs): MeTe study | |
| Phase 3Authorised | not given | Phase III randomized sequential open-label study to evaluate the efficacy of FOLFOX + panitumumab followed by FOLFIRI + bevacizumab (Sequence 1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (Sequence 2) in untreated patients with wild-type RAS metastatic, primary left-sided, unresectable colorectal cancer: The CR-SEQUENCE | |
| Phase 2Authorised | not given | Sequential or up-front triple treatment with durvalumab, tremelimumab and bevacizumab for non-resectable hepatocellular carcinoma (HCC) patients (MONTBLANC) | |
| Phase 2Ended | not given | Clinical investigation evaluating safety and efficacy of selective intra-arterial 166Holmium radiation therapy in combination with atezolizumab and bevacizumab for non resectable Hepatocellular carcinoma (HOLMBRAVE) | |
| Phase 2Authorised | not given | Multisite open-label randomized phase II clinical trial in newly diagnosed glioblastoma treated by concurrent TemoRadiation and adjuvant temozolomide +/- ultrasound-induced blood brain barrier opening - SonoFIRST | |
| Phase 4Authorised | not given | An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion | |
| Phase 2Authorised | not given | ETOP 18-21 AMAZE-lung: A multicentre single-arm phase II trial of amivantamab, lazertinib plus bevacizumab in patients with EGFR-mutant advanced NSCLC with progression on previous third-generation EGFR-TKI. | |
| Phase 2Authorised | not given | Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS) | |
| Phase 3Authorised | not given | Bevacizumab for the treatment of cerebral RAdiation Induced NecrosiS (BRAINS) study: A multicenter, open-label, randomized clinical trial to assess the clinical efficacy and cost-effectiveness of bevacizumab versus corticosteroids as first-line treatment in patients with symptomatic cerebral radiation necrosis after radiation for high grade glioma or brain metastases | |
| Phase 2Authorised | not given | Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study (Combi G-Vax) | |
| Phase 2Authorised | not given | A randomized, 2-arm non-comparative phase II study on the efficacy of atezolizumab and Roche bevacizumab (Atezo/Bev) followed by on-demand selective TACE (sdTACE) upon detection of disease progression or of initial synchronous treatment with TACE and Atezo/Bev on objective response rate in the treatment of unresectable hepatocellular carcinoma patients (DEMAND) | |
| Phase 2Ended | not given | Breaking the big Five Barriers of Brain Metastasis: A prospective phase II, open-label, multi-center trial of combined nivolumab, ipilimumab and bevacizumab together with 2 cycles of induction chemotherapy in patients with non-squamous non-small-cell lung cancer (NSCLC) metastatic to the brain CA209-7WF / Break B5-BM-NSCLC | |
| Phase 2Ended | not given | Impact of neoadjuvant immunotherapy in early stage breast cancer before standard therapy (BIS-Program) | |
| Phase 3Authorised | not given | The ABC-HCC Trial: A Phase IIIb, randomized, multicenter, open-label trial of Atezolizumab plus Bevacizumab versus transarterial Chemoembolization (TACE) in intermediate-stage HepatoCellular Carcinoma | |
| Phase 2Authorised | not given | A phase 1/2 study exploring the safety and activity of Trifluridine/Tipiracil in combination with Capecitabine and Bevacizumab in metastatic colorectal cancer patients. The TriComB trial | |
| Phase 2Authorised | not given | Prospective, randomized, open, multicenter Phase II trial to investigate the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment of metastatic colorectal cancer - FIRE-8 - AIO-KRK/YMO-0519 | |
| Phase 1/2Authorised | not given | A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma | |
| Phase 2Authorised | not given | Multicenter phase II study of preoperative chemoradiotherapy with CApecitabine plus Temozolomide in patients with MGMT silenced and microsatellite stable locally Advanced RecTal Cancer: the CATARTIC trial | |
| Phase 2Authorised | not given | Sequential immunochemotherapy treatment with Pembrolizumab plus Dendritic Cell (DC) Vaccine followed by Trifluridine/Tipiracil plus Bevacizumab in refractory mismatch-repair-proficient (pMMR) or microsatellite-stable (MSS) metastatic colorectal cancer | |
| Phase 2Authorised | not given | A single arm phase II study evaluating intracranial efficacy of Sacituzumab govitecan (SG) with bevacizumab in patients with asymptomatic brain metastases from non-small cell lung cancer (NSCLC) | |
| Phase 3Ended | not given | A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent, or Recurrent Carcinoma of the Cervix (BEATcc ) | |
| Phase 2Authorised | not given | MATVAC-1 : EVALUATION OF UCPVAX VACCINE +/- PEMBROLIZUMAB COMBINED WITH STANDARD TREATMENT AS ADJUVANT THERAPY IN PATIENTS WITH UNMETHYLATED MGMT GLIOBLASTOMA | |
| Phase 2Authorised | not given | Safety of Atezolizumab/Bevacizumab in liver transplanted patients with advanced hepatocellular carcinoma (IMMUNO-TH) | |
| Phase 1/2Authorised | not given | AcSé-ESMART: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors | |
| Phase 2Authorised | not given | PRIDE: A phase IIb, open-label, multicenter study of radiochemotherapy with isotoxic dose escalation and protective VEGF inhibition using bevacizumab in the treatment of patients with first diagnosis of IDH wild-type, MGMT unmethylated glioblastoma | |
| Phase 3Authorised | not given | HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN : Randomised, international and multicentric phase 3 study that evaluates 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma, and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy | |
| Phase 1/2Authorised | not given | BORTEZOMIB SENSITIZATION OF RECURRENT GRADE-4 GLIOMA WITH UNMETHYLATED MGMT PROMOTER TO TEMOZOLOMIDE. PHASE IB/II. (BORTEM 17) | |
| Phase 2Authorised | not given | MEMMAT - Medulloblastoma European Multitarget Metronomic Anti-Angiogenic Trial - A Phase II study of metronomic and targeted anti-angiogenesis therapy for children with recurrent/progressive medulloblastoma, ependymoma, ATRT and rare CNS tumors | |
| Phase 2Authorised | not given | Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study | |
| Phase 2Authorised | not given | FFCD - 1703 - POCHI : PEMBROLIZUMAB in combination with XELOX or FOLFOX-BEVACIZUMAB in patients with Microsatellite Stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof-of-concept study. Phase II – non-randomised- multicentre. | |
| Phase 2/3Authorised | not given | rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma | |
| Phase 1/2Authorised | not given | BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma | |
| Phase 3Authorised | not given | An open-label, randomised, phase III study comparing trifluridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy (SOLSTICE study). | |
| Phase 2Ended | not given | A multicentre phase II, open-label, non-randomized study evaluating Platinum-Pemetrexed-Atezolizumab ( Bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after Targeted therapies | |
| Phase 2Authorised | not given | Biomarker discovery randomized phase IIb trial with carboplatin-cyclophosphamide versus paclitaxel with or without atezolizumab as first-line treatment in advanced triple negative breast cancer | |
| Phase 2Authorised | not given | MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination | |
| Phase 2Ended | not given | Fecal Microbiota Transplant (FMT) combined with Atezolizumab plus Bevacizumab in Patients with HepatoCellular Carcinoma who failed to respond to prior Immunotherapy – the FAB-HCC pilot study | |
| Phase 3Authorised | not given | BEVERLY: A randomized open-label phase 3 trial comparing bevacizumab + erlotinib vs erlotinib alone as first line treatment of patients with EGFR mutated advanced non squamous non small cell lung cancer | |
| Phase 2Authorised | not given | Quality of life and neurocognitive functioning in diffuse low-grade glioma patients treated with Temozolomide: feasibility study - TEMOIN | |
| Phase 2Ended | not given | Multicenter randomized controlled trial of the value of intravitreal anti-VEGF injections as initial then adjuvant treatment in Coats' disease | |
| Phase 2Authorised | not given | Tocotrienol and bevacizumab in metastatic colorectal cancer. A randomized phase II marker trial | |
| Phase 2Authorised | not given | Neoadjuvant treatment in rectal cancer with radiotherapy followed by atezolizumab and bevacizumab - TARZAN | |
| Phase 2Authorised | not given | FoRT 05- BEAT Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-small-cell lung cancer patients | |
| Phase 2Authorised | not given | A PROSPECTIVE, MULTICENTER, OPEN-LABEL, PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OR SELECTIVE INTERNAL RADIATION THERAPY PLUS XELOX, BEVACIZUMAB AND ATEZOLIZUMAB ( IMMUNE CHECKPOINT INHIBITOR) IN PATIENTS WITH LIVER-DOMINANT METASTATIC COLORECTAL CANCER | |
| Phase 2Authorised | not given | Non‐Randomized, Open‐Label, Prospective Phase II Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer After Standard First‐Line Treatment. STROBE | |
| Phase 3Authorised | not given | Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuxiMAb or BevacizumaB | |
| Phase 2Ended | not given | PEMBROLIZUMAB IN MMR-PROFICIENT METASTATIC COLORECTAL CANCER PHARMACOLOGICALLY PRIMED TO TRIGGER DYNAMIC HYPERMUTATION STATUS - THE ARETHUSA TRIAL | |
| Phase 2/3Authorised | not given | Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for resectable colorectal peritoneal metastases: a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). | |
| Phase 4Authorised | not given | Evaluating the safety of shortened infusion tiMes for dIfferent oNcological immUnoThErapies; An observational prospective study (MINUTE) | |
| Phase 2Ended | not given | BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma | |
| Phase 3/4Authorised | not given | Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-Associated Macular Degeneration | |
| Phase 2Authorised | not given | NEOADJUVANT ATEZOLIZUMAB AND ADJUVANT ATEZOLIZUMAB + BEVACIZUMAB IN COMBINATION WITH PERCUTANEOUS RADIOFREQUENCY ABLATION OF SMALL HCC: A MULTICENTER RANDOMIZED PHASE II TRIAL | |
| Phase 2Authorised | not given | Phase II, single-arm, open-label interventional clinical trial to evaluate the role of anthracycline infusion after radiotherapy (RT) in pediatric and young adult patients with glioblastoma (pGBM) | |
| Phase 3Authorised | not given | A randomized phase III trial with lomustine versus lomustine and bevacizumab for patients with recurrent glioblastoma | |
| Phase 2Authorised | not given | Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA trial | |
| Phase 2Authorised | not given | Regorafenib as second-line treatment of patients with RAS-mutant advanced colorectal cancer: a multicentre, phase 2 study - STREAM-2 | |
| Phase 2Authorised | not given | BEvacizumab plus Trifluridine/tipiracil in a bi-WEEkly administration to reduce grade 3-4 Neutropenia in patients with mCRC: A prospective, multicenter, comparative, randomized GERCOR G-124 BETWEEN phase II study | |
| Phase 2Authorised | not given | BASECOVID - Bevacizumab in post-acute sequelae of COVID-19 : Efficacy and Safety (Pilot Study) | |
| Phase 1/2Authorised | not given | FIDES: Focused Ultrasound-mediated Blood-Brain Barrier Opening In Pontine Diffuse Midline Glioma (DMG) to Enhance Systemic Therapy with Temozolomide – an exploratory pilot and feasibility trial | |
| Phase 4Authorised | not given | A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial | |
| Phase 2Authorised | not given | A phase II, randomized, open-label, national, multicenter study evaluating the efficacy and safety of the combination of atezolizumab and bevacizumab as neoadjuvant plus adjuvant treatment in hepatocellular carcinoma (ASPIRE) | |
| Phase 2Authorised | not given | Ipilimumab and nivolumab plus temozolomide and capecitabine for patients with chemo-refractory pMMR, MGMT silenced metastatic colorectal cancer: The MAYA2 trial | |
| Phase 2Authorised | not given | PRODIGE 115 (FFCD 2406) ULYSSE : A phase II, open-label, non-comparative, randomized study of second-line doublet chemotherapy (FOLFOX or FOLFIRI) plus Fruquintinib versus doublet chemotherapy (FOLFOX or FOLFIRI) plus Bevacizumab in metastatic colorectal cancer | |
| Phase 2Authorised | not given | IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease | |
| Phase 4Authorised | not given | PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer | |
| Phase 3Authorised | not given | First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of systemic chemotherapy (ADJUPANET) | |
| Phase 2Authorised | not given | METIMMOX-3: Using Tumor Mutational Status as Selection Biomarker for First-Line Therapy with Short-Course Oxaliplatin-Based Chemotherapy and Bevacizumab Alternating with Tislelizumab in Metastatic MSS/pMMR Colorectal Cancer | |
| Phase 2Authorised | not given | A phase 2, open-label, Multicenter, Randomized study of Trastuzumab Deruxtecan versus investigator’s choice chemotherapy in recurrent ovarian cancer that progressed on prior PARP inhibitor therapy: TROY (APGOT-OV14) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026